1. Home
  2. IBO vs CDT Comparison

IBO vs CDT Comparison

Compare IBO & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IBO
  • CDT
  • Stock Information
  • Founded
  • IBO 2018
  • CDT 2019
  • Country
  • IBO United States
  • CDT United States
  • Employees
  • IBO N/A
  • CDT N/A
  • Industry
  • IBO
  • CDT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IBO
  • CDT Health Care
  • Exchange
  • IBO NYSE
  • CDT Nasdaq
  • Market Cap
  • IBO 5.8M
  • CDT 5.2M
  • IPO Year
  • IBO 2024
  • CDT N/A
  • Fundamental
  • Price
  • IBO $0.69
  • CDT $1.93
  • Analyst Decision
  • IBO
  • CDT
  • Analyst Count
  • IBO 0
  • CDT 0
  • Target Price
  • IBO N/A
  • CDT N/A
  • AVG Volume (30 Days)
  • IBO 635.2K
  • CDT 290.9K
  • Earning Date
  • IBO 08-23-2025
  • CDT 08-11-2025
  • Dividend Yield
  • IBO N/A
  • CDT N/A
  • EPS Growth
  • IBO N/A
  • CDT N/A
  • EPS
  • IBO N/A
  • CDT N/A
  • Revenue
  • IBO N/A
  • CDT N/A
  • Revenue This Year
  • IBO N/A
  • CDT N/A
  • Revenue Next Year
  • IBO N/A
  • CDT N/A
  • P/E Ratio
  • IBO N/A
  • CDT N/A
  • Revenue Growth
  • IBO N/A
  • CDT N/A
  • 52 Week Low
  • IBO $0.36
  • CDT $1.90
  • 52 Week High
  • IBO $6.17
  • CDT $622.50
  • Technical
  • Relative Strength Index (RSI)
  • IBO N/A
  • CDT 28.61
  • Support Level
  • IBO N/A
  • CDT $1.94
  • Resistance Level
  • IBO N/A
  • CDT $2.31
  • Average True Range (ATR)
  • IBO 0.00
  • CDT 0.16
  • MACD
  • IBO 0.00
  • CDT 0.04
  • Stochastic Oscillator
  • IBO 0.00
  • CDT 7.02

About IBO IMPACT BIOMEDICAL INC

Impact BioMedical Inc focuses on the advancement of drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. The company is also developing open-air defense initiatives, which curb transmission of air-borne infectious diseases, such as tuberculosis and influenza. Its technologies inlcude Linebacker, Laetose, 3F, and Equivir.

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Share on Social Networks: